Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, October 22, 2025
Cambrex announced a $120 million investment aimed at expanding active pharmaceutical ingredient (API) manufacturing capacity in the United States, reinforcing domestic supply chain resilience and supporting the growing peptide therapeutics segment.
read more
Cambrex announced Tom Loewald has been named Chief Executive Officer and a member of the company’s Board of Directors, effective September 7th.
read more
Cambrex announced that it is nearing the completion of a 5-year, $100-million-dollar investment strategy, one year ahead of schedule.
read more
Tuesday, September 26, 2017
Cambrex has completed the installation of new, large scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden.
read more
Cambrex announced that their stability storage business, Q1 Scientific, has opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to the pharmaceutical, medical device ...
read more
Cambrex has announced three senior appointments to further support the Contract development and Manufacturing Organization company.
read more
Tuesday, November 20, 2018
Cambrex has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million.
read more
Cambrex has entered into a definitive agreement to acquire Halo Pharma, a dosage form CDMO, for approximately $425 million.
read more
Monday, September 26, 2016
Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has agreed to acquire PharmaCore Inc., a privately-owned company specializing in developing, manufacturing and scaling up small ...
read more
Monday, November 21, 2022
Cambrex entered an agreement to acquire Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
read more
Cambrex announced it is expanding its solid form screening and crystallization process development facility in Edinburgh, Scotland, doubling the current footprint to 15,000 sq. ft.
read more
Tuesday, September 25, 2018
Cambrex announced that it is to establish a center of excellence for API clinical supply and process development at its site in High Point, North Carolina.
read more
Wednesday, September 07, 2016
Cambrex Corporation a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has announced a SEK 72 million ($9 million) investment to expand large scale manufacturing capacity at its Karlskoga facility in ...
read more
Wednesday, November 25, 2020
Cambrex is expanding its mid-scale and large-scale API manufacturing capacity in Charles City, Iowa.
read more
Cambrex announced the expansion of its stability storage business, Q1 Scientific, which offers environmentally-controlled stability storage services to the pharmaceutical, medical device, and life sciences industries.
read more